A trial of the screening for high risk of preeclampsia population and monitoring efficacy of aspirin by AI-assisted fundus examination and plasma biological markers

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036780

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

control group: NICE standard evaluation

experimental group:AI-assisted fundus examination, plasma biological markers and NICE standard evaluation

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Gestational weeks between 12+0 weeks and 15+6 weeks; 2. Aged between 18 years old and 45 years old; 3. Single pregnancy; 4. no major fetal malformation; 5. Consent to periodic medical examinations and delivery at our hospital.

Exclusion criteria

Exclusion criteria: 1. Taking aspirin; 2. Contraindications for the use of aspirin.

Design outcomes

Primary

Measure	Time frame
incidence rate of PE;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
pregnancy outcome;fundus examination;	—

Countries

China

Contacts

Public ContactXiaolin Hua

Shanghai First Maternity And Infant Hospital

huaxiaolin_sh@163.com+86 13764509708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026